Issue link: https://www.e-digitaleditions.com/i/895564
8 November 2017 Tablets & Capsules A rapid vehicle-screening approach for formulating a low- solubility compound into liquid-filled capsules. Amol Kheur, Anil Kane, Mohammad Aleem, Maureen McLaughlin, Kiran Kumar Tumbalam, and Shivaprakash Poojary. January 2014, p. 10. Recent challenges in dissolution testing, including USP initiatives. Vivian A. Gray, January 2012, p. 28. Reducing risk in the development and manufacture of tablets using rapid compressibility assessments. Dipankar Dey and Michael Gamlen. September 2011, p. 28. The role of NIR spectroscopy in meeting the PAT chal- lenge. Frederick H. Long. March 2007, p. 20. A simple test to differentiate gelatin from hypromellose cap- sules. Enrique Requejo Gabás, Fernando Díez Menendez, Luis Polo Díez, and Nour Kayali. July 2013, p. 16. Simulated tabletting, real-world pay-off. Kendal Pitt. Back Page, September 2010, p. 56. Tablet exam: Using dynamic compaction analysis to ensure successful formulations. Joe Domingue and Michael Gamlen. May 2016, p. 28. Tabletability, compactibility, and compressibility: What's the difference? Robert Sedlock. September 2016, p. 19. Testing powder flowability. Robert G. McGregor. March 2011, p. 20. Tooling supplier, university seek cure for sticking. July 2013, p. 40. Tracking bulk density to maximize tablet production. Vinnie Hebert. March 2016, p. 27. Understanding maximum compression force. Kevin Queensen. September 2015, p. 10. Update on the FDA's spectral library of excipients. Philip H. Merrell, Lucinda Buhse, and Jason D. Rodriguez. July 2013, p. 27. Using an automated workstation to improve operations and simplify investigations. C.J. Moynihan and Robert C. Houser. May 2012, p. 23. Using fundamental powder properties to optimize flowa- bility. Greg Mehos, Mike Eggleston, Tristan Trautman, Matthew Freeman, and Nicole Stevens-Murphy. October 2017, p. 11. Using low-field MRI to improve tablet dissolution test- ing. James Butler and Kevin Nott. January 2010, p. 25. Using static image analysis to size crystalline particles. Patrick O'Hagan, Kerry Hasapidis, Vincent Chapeau, and Christian Godino. May 2008, p. 30. Using terahertz spectroscopy to map tablet cores and coat- ings. Mark Sullivan, Edward King, Eiji Kato, David Heaps, Richard McKay, and Xiao Hua Zhou. October 2013, p. 10 What standard? Investigation raises questions about DNA testing. Evan Hansen. April 2015, p. 32B. You can't correct for randomness. Ben Locwin. Back Page, October 2013, p. 48. Anti-counterfeit techniques Detecting counterfeit drug products via impurity map- ping. Aurélie Bart, Ziyang Su, Karl V. Wood, Stephen R. Byrn, and M. Teresa Carvajal. October 2009, p. 24. The evolution of on-dose product identification. Edward S. Novit. October 2017, p. 33. FDA hones guidance on PCIDs. Peter M. O. Wong. Back Page, April 2012, p. 56. Fighting counterfeits requires on-dose protection. Dean Hart. July 2009, p. 34. On-dose authentication: Walking softly, prepared to stick. Peter M.O. Wong. March 2011, p. 28. On-dose product identification. Craig Leidholm. Eye on Excipients, October 2017, p. 43. Track and trace: Options for compliance. Mark Feher. May 2013, p. 12. Auditing Excipients in the news. Matthew Knopp. Back Page, July 2013, p. 48. Five questions to ask your suppliers to ensure quality and control cost. John Davidson and David Simpson. October 2012, p. 32B. GMP compliance: The top seven pitfalls. Greta Houlahan. January 2012, p. 32B. Gaining reassurance from third-party auditing. Edward Wyszumiala and Manny Jimenez. January 2010, p. 32B. Have a plan before the FDA arrives. Bryan J. Coleman. Back Page, October 2016, p. 52. On-site audits of excipient suppliers. Irwin B. Silverstein and Jim Morris. Eye on Excipients, September 2014, p. 41. Safety evaluations of new excipients. Christopher DeMerlis, Elaine V. Knight, R. Christian Moreton, and Robert E. Osterberg. Eye on Excipients, April 2011, p. 39. Stability testing. Philip H. Merrell. Eye on Excipients, October 2012, p. 33. The 10 most common 483s and how to avoid them. Carol Tousey. October 2010, p. 24. Third-party auditing. Philip H. Merrell. Eye on Excipients, March 2010, p. 37. Bioavailability Improving the bioavailability APIs for delivery in oral solid dosage forms. Robert J. Timko. July 2016, p. 29. Functional lipids and self-emulsifying drug delivery systems (SEDDS) to overcome the poor solubility and permeability of today's APIs. John K. Tillotson. Eye on Excipients, May 2016, p. 41. Using silica to enhance API bioavailability. William McCarthy. Eye on Excipients, May 2017, p. 41. Blending Effect of sampling methods on vitamin D blending uni- formity. Wenming Zeng, Dan Wang, and Doug Roper. October 2016, p. 17.